MN-DPDP ENHANCEMENT PATTERNS OF HEPATOCELLULAR LESIONS ON MR-IMAGES

被引：45

作者：

VOGL, TJ

HAMM, B

SCHNELL, B

MCMAHON, C

BRANDING, G

LISSNER, J

WOLF, KJ

机构：

[1] Department of Radiology, University of Munich, Munich, 8000

[2] Department of Radiology, Klinikum Steglitz, University of Berlin, Berlin

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 01期

关键词：

CONTRAST ENHANCEMENT; LIVER; FOCAL NODULAR HYPERPLASIA; LIVER NEOPLASMS; DIAGNOSIS; MR; MANGANESE;

D O I：

10.1002/jmri.1880030110

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The recently developed paramagnetic hepatobiliary contrast agent manganese dipyridoxyl diphosphate (DPDP) was evaluated in eight patients. Pathologic diagnoses included five hepatocellular carcinomas, two cirrhoses, and one focal nodular hyperplasia. T1-weighted spin-echo and gradient-echo images were obtained after intravenous injection of 5 or 10 mumol/kg Mn-DPDP; these were compared with unenhanced T1-weighted spin-echo and gradient-echo images and T2-weighted spin-echo images. In all patients with lesions of hepatocellular origin, focal areas of increased enhancement were seen in the lesions after administration of Mn-DPDP. In the cirrhotic livers, these areas corresponded to foci of hepatic regeneration. In all patients, the signal-to-noise ratio in normal liver tissue increased significantly after injection of Mn-DPDP. Signal intensity in the six primary liver tumors was further increased, so that they appeared hyperintense relative to surrounding liver tissue on all T1-weighted images. Conspicuity and demarcation of all lesions were improved on Mn-DPDP-enhanced images.

引用

页码：51 / 58

页数：8

共 30 条

[1]

Lauffer RB, Hepatobiliary agents for MRI: rationale and preliminary evaluation, Liver imaging: current trends and new techniques, pp. 365-373, (1990)

[2]

Rocklage SM, Cacheris WP, Quay SC, Hahn FE, Raymond KN, Manganese (II) N, N'‐dipyridoxylethylenediamine‐N, N'‐diacetate 5,5′‐bis(phosphate): synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement, Inorg Chem, 28, pp. 477-485, (1989)

[3]

Rocklage SM, Van Wagoner M, Hepatobiliary contrast agents: an overview of the development of manganese di‐pyridoxyl diphosphate (Mn‐DPDP), Liver imaging: current trends and new techniques, pp. 374-383, (1990)

[4]

Elizondo G, Fretz CJ, Stark DD, Et al., Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging, Radiology, 178, pp. 73-78, (1991)

[5]

Lim KO, Stark DD, Leese PT, Pfefferbaum A, Rocklage SM, Quay SC, Hepatobiliary MR imaging: first human experience with Mn DPDP, Radiology, 178, pp. 79-82, (1991)

[6]

Hamm B, Vogl TJ, Branding G, Et al., MR imaging of focal liver lesions with Mn‐DPDP as a new hepatobiliary contrast agent: initial clinical results in 40 patients, Radiology, 182, pp. 167-174, (1992)

[7]

Edelman RR, Hesselink JR, Clinical magnetic resonance imaging, pp. 150-166, (1990)

[8]

Stark DD, Felder RC, Wittenberg J, Et al., Magnetic resonance imaging of cavernous hemangioma of the liver: tissue‐specific characterization, AJR, 195, pp. 213-222, (1985)

[9]

Ohtomo K, Itai Y, Furui S, Yashiro N, Yoshikawa K, Lio M, Hepatic tumors: differentiation by transverse relaxation time (T2) of magnetic resonance imaging, Radiology, 155, pp. 421-423, (1985)

[10]

Li KC, Glazer GM, Quint LE, Et al., Distinction of hepatic cavernous hemangioma from hepatic metastases with MR imaging, Radiology, 169, pp. 409-415, (1988)

← 1 2 3 →